News - FAIS Africa

June 23, 2022 | |

Accepted Abstract Presentations & 140 Trainee Travel Awards for Cytokines 2022 Hybrid Joint Meeting with ILC4 in Hawaii

  Congratulations to the 96 ICIS Student/Postdoc Member Travel Award winners for Cytokines 2022 Hybrid Joint Meeting (generously sponsored by the Milstein Family, Vilcek Foundation and ICIS members) and 44 Student/Postdoc Travel Award winners for the 4th International Conference on Innate Lymphoid Cells (ILC4), sponsored by a generous grant from Sandler Asthma Basic Research Center (SABRE Center) at UCSF. To view the award winners, please click here for Cytokines 2022 and here for ILC4. We hope that all those we…

June 14, 2022 | |

26th Annual Jonathan Lax Award Lecture

The Lax Lecture is a public lecture hosted by The Wistar Institute where leading international HIV scientists interact with local researchers, clinicians, and patient advocates. Dr. Mike McCune, M.D., Ph.D., Head of the HIV Frontiers and Biotechnology Accelerator Programs at the Gates Foundation, will deliver this year’s lecture, “Bringing Safe and Effective "Curative" Interventions for HIV and Sickle Cell Disease to Resource-limited Parts of the World.” Following the Lecture, a panel of global HIV cure community advocates will discuss the…

May 18, 2022 | Call For Nominations - IUIS Elections 2022-2025 | https://iuis.org/

Call For Nominations – IUIS Elections 2022-2025

IUIS Executive Committee and Council Elections 2022-2025 Call for Nominations The IUIS Constitution requires elections for governance every three years, therefore, the 2022 elections will go ahead in the absence of an in-person General Assembly, as approved by the IUIS Council. The triennial IUIS Executive Committee and Council Elections will take place virtually from 1 October to 15 October, 2022, prior to the 18th Virtual IUIS General Assembly on Sunday, 20 November, 2022. As a valued member of the IUIS,…

February 18, 2022 | A new TB vaccine – is it cost-effective and efficient? | Immunopaedia.org.za

A new TB vaccine – is it cost-effective and efficient?

Immunology research update from www.immunopaedia.org.za A new vaccine against tuberculosis may prove to be a cost-effective and efficient preventative management strategy for a pandemic that has been overshadowed by the dawn of COVID-19. The COVID-19 pandemic has drawn, justifiably, much needed research attention away from other disease areas including tuberculosis (TB) research. Mycobacterium tuberculosis has taken advantage of the shortage of attention from respiratory clinicians and scientists. Increasing deaths from TB in 2021 followed by a negatively impacted treatment and diagnosis platforms are…

February 16, 2022 | More SARS-CoV-2 variants? | Immunopaedia.org.za

More SARS-CoV-2 variants?

Immunology research update from www.immunopaedia.org.za A recent paper by Foix, et al., has reported on the potential of existing strains of SARS-CoV-2, and future variants to escape the immune system’s cytotoxic T cell response. Genetically, HLAs determine the outcome of the T cell response in humans. This means that individuals share different and specific HLAs between them all in an effort to recognise pathogens based on their epitopes. Due to the vast amounts of differing HLA molecules, in addition to viral epitopes, to investigate the immune…

February 11, 2022 | HIV vaccine progress | Immunopaedia.org.za

HIV vaccine progress

Immunology research update from www.immunopaedia.org.za In a recent paper, Ziyang, et al., have produced novel insights into and further developed an HIV vaccine through the use of a unique trimer in order to develop Tier-2 neutralizing antibodies within a murine model. HIV, a deadly virus that researchers today are still trying to understand, has killed 36.3 million people worldwide. A vaccine, key to preventing the spread and combatting severity of the virus, is still far from development. However, in this present…

1 2 3 145